{
    "nctId": "NCT02391194",
    "briefTitle": "Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery",
    "officialTitle": "A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 27,
    "primaryOutcomeMeasure": "Safety of AVB-620 as assessed by the incidence of adverse events and abnormal laboratory values",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ductal carcinoma in situ (DCIS) or Stage I-III, primary invasive carcinoma of the breast\n* Primary surgical treatment is planned to be a mastectomy or lumpectomy. Sentinel lymph node (LN) biopsy or axillary LN dissection (ALND) is planned as part of the subject's therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Adequate renal function\n* Lab values (hematology and chemistry) within institution's normal laboratory limits\n* Willing to remain on-site for approximately 24 hours after administration of AVB-620 or, if required, stay overnight after the surgical procedure\n* If the subject received neoadjuvant therapy, residual tumor is present (to be determined by the primary surgeon)\n* If the subject received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within institution's normal limits\n* Subject has the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Recurrent ipsilateral breast cancer\n* Prior neoadjuvant chemotherapy or biologic therapy for current clinically or biopsy-proven node positive breast cancer within 4 weeks before the planned surgery.\n* Open surgery in the ipsilateral breast within 1 year of AVB-620 administration\n* History of radiation therapy to ipsilateral breast\n* Abnormal cardiac rhythm not controlled with medication, history of stroke, coronary events, and/or heart failure within 1 year of AVB-620 administration\n* Diagnosis of autoimmune disorders\n* History of drug-related anaphylactic reactions or allergic reactions; subjects with an active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma requiring oral corticosteroids will be excluded\n* History of renal disease or current evidence of renal disease\n* Current diagnosis of any other active or clinically significant non-breast cancer\n* Systemic investigational drug of any kind within 6 weeks of AVB-620 administration\n* Pregnant or breast feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}